Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 4/20 | 0.60 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.53 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.53 |
| ▸ | LTA4H | P09960 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.52 |
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphenylether SCHEMBL29220492 | 0.94 | CYP2A6 (0.65) | CYP11B2CYP11B1CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL21882447 | 0.90 | MAPT (0.55) | CYP11B2CYP11B1CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL21882446 | 0.87 | CYP2A6 (0.54) | CYP11B2CYP11B1CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL29468039 | 0.85 | CYP2A6 (0.79) | CYP11B2CYP11B1CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL3400752 | 0.85 | CYP2A6 (0.79) | CYP11B2CYP11B1CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL25985498 | 0.85 | CYP11B2 (0.53) | CYP11B2CYP11B1CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL25985506 | 0.85 | CYP11B2 (0.53) | CYP11B2CYP11B1CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL21345924 | 0.85 | CYP3A4 (0.57) | CYP11B2CYP11B1CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL25985458 | 0.84 | CYP19A1 (0.55) | CYP11B2CYP11B1CYP3A4ALDH1A1CYP19A1 | |
| SCHEMBL27968872 | 0.84 | LMNA (0.69) | CYP11B2CYP11B1ALDH1A1CYP19A1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11491153-B2 | Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2022-11-08 | — | — | US | disclosed |
| CN-1147492-C | New metal protease inhibitors, its preparing method and their medicinal composition containing them | ɪά��ʵ���� | 2004-04-28 | — | — | CN | disclosed |
| EP-1065209-B1 | Metalloprotease inhibitors, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-05-02 | — | — | EP | disclosed |
| US-6339092-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, ARTHROSIS, TUMOUR INVASION AND GROWTH, INCLUDING MALIGNANT SPREAD AND THE FORMATION OF METASTASES, ULCERATIONS, ATHEROSCLEROSIS | ADIR ET COMPAGNIE (FR) | 2002-01-15 | — | — | US | disclosed |
| EP-1065209-A1 | Metalloprotease inhibitors, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11491153-B2 | Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity | BTK, SYK, LCK | CYP11B2 4418/4885CYP11B1 4206/4885CYP2A6 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.